1239 related articles for article (PubMed ID: 25231316)
1. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
[TBL] [Abstract][Full Text] [Related]
3. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.
He Y; Li J; Li W; Lustigman S; Farzan M; Jiang S
J Immunol; 2006 May; 176(10):6085-92. PubMed ID: 16670317
[TBL] [Abstract][Full Text] [Related]
4. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
[TBL] [Abstract][Full Text] [Related]
5. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
Tai W; Zhang X; He Y; Jiang S; Du L
Antiviral Res; 2020 Jul; 179():104820. PubMed ID: 32405117
[TBL] [Abstract][Full Text] [Related]
6. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
7. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
8. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
[TBL] [Abstract][Full Text] [Related]
9. Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein.
Van Egeren D; Novokhodko A; Stoddard M; Tran U; Zetter B; Rogers M; Pentelute BL; Carlson JM; Hixon M; Joseph-McCarthy D; Chakravarty A
PLoS One; 2021; 16(4):e0250780. PubMed ID: 33909660
[TBL] [Abstract][Full Text] [Related]
10. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
Dai L; Zheng T; Xu K; Han Y; Xu L; Huang E; An Y; Cheng Y; Li S; Liu M; Yang M; Li Y; Cheng H; Yuan Y; Zhang W; Ke C; Wong G; Qi J; Qin C; Yan J; Gao GF
Cell; 2020 Aug; 182(3):722-733.e11. PubMed ID: 32645327
[TBL] [Abstract][Full Text] [Related]
11. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening.
Yang X; Duan H; Liu X; Zhang X; Pan S; Zhang F; Gao P; Liu B; Yang J; Chi X; Yang W
J Virol; 2023 Jul; 97(7):e0061023. PubMed ID: 37367229
[TBL] [Abstract][Full Text] [Related]
12. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
Wang L; Shi W; Chappell JD; Joyce MG; Zhang Y; Kanekiyo M; Becker MM; van Doremalen N; Fischer R; Wang N; Corbett KS; Choe M; Mason RD; Van Galen JG; Zhou T; Saunders KO; Tatti KM; Haynes LM; Kwong PD; Modjarrad K; Kong WP; McLellan JS; Denison MR; Munster VJ; Mascola JR; Graham BS
J Virol; 2018 May; 92(10):. PubMed ID: 29514901
[TBL] [Abstract][Full Text] [Related]
13. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.
Tang XC; Agnihothram SS; Jiao Y; Stanhope J; Graham RL; Peterson EC; Avnir Y; Tallarico AS; Sheehan J; Zhu Q; Baric RS; Marasco WA
Proc Natl Acad Sci U S A; 2014 May; 111(19):E2018-26. PubMed ID: 24778221
[TBL] [Abstract][Full Text] [Related]
14. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
[TBL] [Abstract][Full Text] [Related]
16. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
17. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
18. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
19. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins.
Wang SF; Tseng SP; Yen CH; Yang JY; Tsao CH; Shen CW; Chen KH; Liu FT; Liu WT; Chen YM; Huang JC
Biochem Biophys Res Commun; 2014 Aug; 451(2):208-14. PubMed ID: 25073113
[TBL] [Abstract][Full Text] [Related]
20. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
